Holen Sie sich die Stockscreener-App
184.71
0.49%
0.90
Schlusskurs vom Vortag:
$183.81
Offen:
$184
24-Stunden-Volumen:
331.61K
Relative Volume:
0.91
Marktkapitalisierung:
$19.68B
Einnahmen:
$3.32B
Nettoeinkommen (Verlust:
$-860.46M
KGV:
-22.20
EPS:
-8.32
Netto-Cashflow:
$-1.04B
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
-4.92%
1J Leistung:
+5.96%
1-Tages-Spanne:
$183.91
$187.42
1-Wochen-Bereich:
$183.91
$187.42
52-Wochen-Spanne:
$141.31
$248.16
Beigene Ltd Adr Stock (BGNE) Company Profile
Firmenname
Beigene Ltd Adr
Sektor
Branche
Telefon
13459494123
Adresse
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Vergleichen Sie BGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BGNE
Beigene Ltd Adr
|
184.71 | 19.68B | 3.32B | -860.46M | -1.04B | -8.32 |
|
ONC
Beigene Ltd Adr
|
234.62 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.15 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.55 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.65 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Beigene Ltd Adr Stock (BGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-12 | Eingeleitet | Macquarie | Outperform |
| 2023-08-17 | Eingeleitet | Jefferies | Buy |
| 2023-07-17 | Eingeleitet | Citigroup | Buy |
| 2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
| 2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
| 2021-10-12 | Eingeleitet | Bernstein | Outperform |
| 2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
| 2021-03-08 | Eingeleitet | China Renaissance | Buy |
| 2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
| 2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2020-07-10 | Herabstufung | CLSA | Buy → Outperform |
| 2020-03-13 | Hochstufung | Macquarie | Underperform → Neutral |
| 2020-02-18 | Fortgesetzt | Goldman | Buy |
| 2020-01-17 | Hochstufung | CLSA | Outperform → Buy |
| 2020-01-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-12-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-11-19 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-13 | Herabstufung | CLSA | Buy → Outperform |
| 2019-11-04 | Bestätigt | Maxim Group | Buy |
| 2019-06-04 | Eingeleitet | Bernstein | Outperform |
| 2019-05-10 | Hochstufung | CLSA | Outperform → Buy |
| 2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
| 2019-01-04 | Herabstufung | CLSA | Buy → Outperform |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-25 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-17 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Beigene Ltd Adr Aktie (BGNE) Neueste Nachrichten
Daiwa Sees Limited Upside for HSI, Prefers HK Stocks w/ Tech Trading Opportunities Like BEIGENE - AASTOCKS.com
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Market Momentum: BeiGene Ltd. ADR (ONC) Registers a -3.93 Decrease, Closing at 232.25 - DWinneX
BeiGene shares tumble over 5% as Q1 revenue misses estimates - Investing.com
BeiGene shares tumble over 5% as Q1 revenue misses estimates By Investing.com - Investing.com South Africa
BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India
BeiGene wins patent challenge against Pharmacyclics - Investing.com
BeiGene wins US patent dispute over cancer drug By Investing.com - Investing.com India
BeiGene wins US patent dispute over cancer drug - Investing.com
BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa
Press Release Distribution & PR Platform - ACCESS Newswire
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com
Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com
RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com
BGNE Page Not Found - Benzinga
Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India
Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com
RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa
RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com
JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India
Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com
Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India
Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com
Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa
Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India
Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com
Bernstein raises BeiGene stock price target to $259 - Investing.com
BeiGene CEO John Oyler sells $10 million in shares - Investing.com India
Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India
BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise
Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa
Beigene’s president Wu Xiaobin sells $13.6 million in shares By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells $10.39 million in shares - Investing.com
BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa
Beigene SVP sells $331,375 in American depositary shares - Investing.com India
JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa
BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India
Finanzdaten der Beigene Ltd Adr-Aktie (BGNE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):